MicrobiotiX

Seoul, South Korea · Biotechnology, Health Care · 35 employees

MicrobiotiX is a bacteriophage therapy company targeting diseases caused by super bacteria (multidrug-resistant bacteria). The company possesses a platform for phage therapy development, which includes a phage library panel targeting multidrug-resistant bacteria, an in silico module, and a cGMP-grade phage manufacturing facility.

Funding history

Series series b — $20.0B — Sep 2025

Recent signals

Sep 03, 2025: Raised $20.0B in Series series b

See plans & pricing → Track MicrobiotiX’s funding, hiring, and signals — with verified contacts — on Fundz.